Utah · A9538

Technetium Tc-99m Pyrophosphate, Diagnostic, Per Study Dose, Up To 25 Millicuries in Utah

Utah Medicare Avg
$44.64
7% above national avg
National Medicare Avg
$41.69
All states combined
Billed Charge (UT)
$92.00
What providers submit
Est. Commercial (UT)
$123.27
National avg: $117.29
Est. Cash / Self-Pay (UT)
$67.32
Typical self-pay discount

Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.

22
Services in UT
6
Providers
N/A
Min Payment
N/A
Max Payment

Top Providers in Utah

Provider Medicare Services
Perry, David DO $44.64 14

Utah Pricing in Context

In Utah, CPT code A9538 (Technetium Tc-99m Pyrophosphate, Diagnostic, Per Study Dose, Up To 25 Millicuries) carries an average Medicare payment of $44.64 — 7% above the national benchmark of $41.69. 6 providers across the state submitted claims for this procedure in 2023, performing 22 total services. Individual payments in UT ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.

The average billed charge in Utah is $92.00, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because Utah sits above the national Medicare average, commercial rates in the state may also run higher than the US median.

Using RAND 2024 commercial-to-Medicare ratios for Medical Supplies procedures, the estimated commercial insurance price in Utah lands near $123.27, with self-pay cash prices typically around $67.32. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.

Frequently Asked Questions

How much does Technetium Tc-99m Pyrophosphate, Diagnostic, Per Study Dose, Up To 25 Millicuries cost in Utah?

The average Medicare payment for Technetium Tc-99m Pyrophosphate, Diagnostic, Per Study Dose, Up To 25 Millicuries in Utah is $44.64, which is 7% above the national average of $41.69. Providers in UT typically bill $92.00 for this procedure.

What does Technetium Tc-99m Pyrophosphate, Diagnostic, Per Study Dose, Up To 25 Millicuries cost with insurance in Utah?

With commercial insurance in Utah, Technetium Tc-99m Pyrophosphate, Diagnostic, Per Study Dose, Up To 25 Millicuries costs an estimated $123.27. Without insurance, the estimated cash price is $67.32. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.

How many providers perform Technetium Tc-99m Pyrophosphate, Diagnostic, Per Study Dose, Up To 25 Millicuries in Utah?

6 providers in Utah billed Medicare for Technetium Tc-99m Pyrophosphate, Diagnostic, Per Study Dose, Up To 25 Millicuries in 2023, performing 22 total services. Medicare payments ranged from N/A to N/A depending on the provider.

Is Technetium Tc-99m Pyrophosphate, Diagnostic, Per Study Dose, Up To 25 Millicuries cheaper in Utah than the national average?

No — Technetium Tc-99m Pyrophosphate, Diagnostic, Per Study Dose, Up To 25 Millicuries costs 7% above the national average in Utah. The state average Medicare payment is $44.64 compared to $41.69 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.

Related

Data sourced from the CMS Medicare Physician and Other Practitioners dataset. See our methodology for details. Retrieved and formatted by PlainProcedure Editorial